Dose-finding Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of CK-3773274 in Adults With Hypertrophic Cardiomyopathy

Inclusion Criteria * Males and females between 18 and 85 years of age at screening. * Body weight is ≥45 kg at screening. * Diagnosed with HCM per the following criteria: * Has left ventricular (LV) hypertrophy with non-dilated LV chamber in the absence of other cardiac disease. * Has minimal wall thickness ≥15 mm (minimal wall thickness ≥13 mm is acceptable with a positive family history of HCM or with a known disease-causing gene mutation). * Adequate acoustic windows for echocardiography. * For Cohorts 1, 2 and 3 has LVOT-G during screening as follows: * Resting gradient ≥50 mmHg OR * Resting gradient ≥30 mmHg and \<50 mmHg with post-Valsalva LVOT-G ≥50 mmHg * For Cohort 4 has resting and post-Valsalva LVOT-G \< 30 mmHg at the time of screening * For Cohort 4 has elevated NT-proBNP \> 300 pg/mL at the time of screening * LVEF ≥60% at screening. * New York Heart Association (NYHA) Class II or III at screening. * Patients on beta-blockers, verapamil, diltiazem, or ranolazine should have been on stable doses for \>4 weeks prior to randomization and anticipate remaining on the same medication regimen during the study. * For Cohort 3: Patients must be taking disopyramide. Patients should have been on stable disopyramide doses for \>4 weeks prior to screening and anticipate remaining on the same medication regimen during the study. Exclusion Criteria * Aortic stenosis or fixed subaortic obstruction. * Known infiltrative or storage disorder causing cardiac hypertroph…